Patient-derived models for soft tissue sarcomas
Development of a Platform of Patient Derived Xenografts (PDX) and 2D/3D Cell Cultures of Soft Tissue Sarcomas (STS): Protocol to Obtain Tumour Material From Patients With STS.
NA · The Netherlands Cancer Institute · NCT02910895
This study is trying to create models from patients' tumors to see how different treatments work for people with soft tissue sarcomas, helping to personalize their care.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | The Netherlands Cancer Institute (other) |
| Locations | 1 site (Amsterdam) |
| Trial ID | NCT02910895 on ClinicalTrials.gov |
What this trial studies
This study focuses on developing patient-derived xenografts (PDX) and 2D/3D cell cultures to better understand soft tissue sarcomas (STS). By utilizing tumor biopsies from patients, the research aims to create models that can predict responses to various treatments, addressing the challenges posed by the diversity of sarcoma subtypes. The goal is to improve treatment personalization and outcomes for patients with STS. The study will involve patients who are willing to undergo tumor sampling during surgery.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with histologically confirmed intermediate to high-grade soft tissue sarcomas.
Not a fit: Patients with known coagulation disorders or those unable to comply with the study protocol may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more effective and personalized treatment options for patients with soft tissue sarcomas.
How similar studies have performed: While the approach of using patient-derived models is gaining traction, the specific application to soft tissue sarcomas remains relatively novel and untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically confirmed diagnosed (non-) metastatic intermediate to high grade STS * Local recurrences are allowed * Age ≥ 18 years * Able and willing to undergo tumour biopsies or tumour sampling during surgery * Localization of sarcoma enables safe biopsy or surgery * Written informed consent Exclusion Criteria: * Known coagulation disorder and/or anticoagulant medication in as far it might interfere with a safe biopsy procedure (to the discretion of the treating physician and attending radiologist) * Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the study
Where this trial is running
Amsterdam
- Netherlands Cancer Institute — Amsterdam, Netherlands (RECRUITING)
Study contacts
- Principal investigator: Rick Haas, MD, PhD — The Netherlands Cancer Institute
- Study coordinator: Rick Haas, MD, PhD
- Email: r.haas@nki.nl
- Phone: +31 20 512 9111
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Soft Tissue Sarcoma, Xenograft Model, 2D/3D Cell Cultures